1-6 of 6
Ira Zackon
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Recent Patterns of Care with BTK Inhibitors and Distribution of Social Determinants of Health Among Patients with CLL/SLL in the US Community Setting

David J Andorsky, Ira Zackon, Thomas W Wilson, Kathleen M Aguilar, Chuck Wentworth, Yunfei Wang, Scott Goldfarb, Keri Yang, Erlene Kuizon Seymour, Mark Balk, Gregory A Maglinte
Journal: Blood
Blood (2023) 142 (Supplement 1): 2413.
https://doi.org/10.1182/blood-2023-172880
Published: 2023
Journal Articles

Treatment Patterns and Overall Survival (OS) Among Patients with Myelodysplastic Syndromes (MDS) Treated in the US Community Oncology Setting: A Real-World Retrospective Observational Study

Roger M. Lyons, Wei-Han Cheng, Laura Moore-Schiltz, Ping Shi, Anders Svensson, Cat N. Bui, Jessica E. Hutti, Ann Marie McNeill, Elizabeth S. Mearns, Archibong Yellow-Duke, Ira Zackon
Journal: Blood
Blood (2022) 140 (Supplement 1): 6938–6939.
https://doi.org/10.1182/blood-2022-163098
Published: 2022
Journal Articles

Characteristics, Blood Counts, Treatments, and Clinical Outcomes of 5871 Patients with Polycythemia Vera Treated in US Community Practices

Roger M. Lyons, Kathleen M. Aguilar, Lavanya Sudharshan, Divea Venkatasetty, Juliet Ndukum, Ira Zackon, Jingbo Yu
Journal: Blood
Blood (2022) 140 (Supplement 1): 13310–13311.
https://doi.org/10.1182/blood-2022-163416
Published: 2022
Journal Articles

Non-Relapse Mortality and Quality of Life with Shared Care after Allogeneic Hematopoietic Cell Transplantation: A Randomized Control Trial

Gregory A. Abel, Haesook T Kim, Ira Zackon, Edwin P. Alyea, III, Alexandra Bailey, John P. Winters, Kenneth R. Meehan, John L Reagan, Jeanna Walsh, Meredith Faggen, Sarah Sinclair, Amy Joyce, Sara Close, Amy Emmert, Isabella Kallassy, John Koreth, Joseph H. Antin, Corey Cutler, Vincent T Ho, Robert J Soiffer
Journal: Blood
Blood (2022) 140 (Supplement 1): 2135–2136.
https://doi.org/10.1182/blood-2022-166996
Published: 2022
Journal Articles

Final Results of a Phase 1/2 Open-Label Study to Assess the Safety, Tolerability and Preliminary Efficacy of Evofosfamide, a Hypoxia-Activated Prodrug, and Dexamethasone with or without Bortezomib in Subjects with Relapsed/Refractory Multiple Myeloma

Jacob P. Laubach, MD, Noopur Raje, MD, Andrew J. Yee, MD, Philippe Armand, MD PhD, Robert L. Schlossman, MD, Jacalyn Rosenblatt, MD, Michael G. Martin, MD, Craig Reynolds, MD, Kenneth H. Shain, MD PhD, Ira Zackon, MD, Laura V. Stampleman, MD, Emily Lai, BS, Aaron M. Caola, BS, Joseph M. Cappuccio, BS, Bradley Rivotto, BS, Kaitlen Reyes, DNP, Alexandra Savell, BS, Patrick Henrick, BS, Tillman Pearce, MD, Damian Handisides, Stew Kroll, Kenneth C. Anderson, MD, Paul G. Richardson, MD, Irene M. Ghobrial, MD
Journal: Blood
Blood (2016) 128 (22): 2122.
https://doi.org/10.1182/blood.V128.22.2122.2122
Published: 2016
Journal Articles

A Phase 1/2 Trial of TH-302 and Dexamethasone without or with Bortezomib (TBorD) in Patients with Relapsed/Refractory Multiple Myeloma

Jacob P. Laubach, MD, Noopur S. Raje, MD, Andrew J. Yee, MD, Philippe Armand, MD PhD, Robert L. Schlossman, MD, Jacalyn Rosenblatt, MD, Jeffrey Matous, MD, Jacquelyn Hedlund, MD, Michael G Martin, MD, Craig Reynolds, MD, Kenneth H. Shain, MD PhD, Ira Zackon, MD, Laura V. Stampleman, MD, Erica N Boswell, BS, Stacey Chuma, BSN, Rebecca Liguori, MS, Stephanie Mar, Damian Handisides, Stew Kroll, Kenneth C. Anderson, MD, Paul G. Richardson, Irene M. Ghobrial, MD
Journal: Blood
Blood (2014) 124 (21): 2142.
https://doi.org/10.1182/blood.V124.21.2142.2142
Published: 2014